News

Proof-of-concept data reported for new multi-antigen engager platform (VY-GAGE) designed to overcome solid tumor defense mechanisms Single-step CD45 allogeneic cell engineering platform (VY-UC) shown to offer significant benefits as alternative to complex gene-editing systems TAMPA, FLORIDA & STOCKHOLM, SWEDEN – ...
Read More

Single-Step CD45-Engager Strategy Generates Immune-Privileged Cells with Abrogation of Host Cellular Immune Responses Being Developed to Eliminate the Need for Complex, Expensive Gene-Editing Approaches while Resolving the Challenges Related to Persistence, Retention of Function, and Avoidance of Host Immune Rejection ...
Read More

TAMPA, FLORIDA & STOCKHOLM, SWEDEN – March 23, 2021 – Vycellix, Inc., an immuno-centric discovery life science company with a focus on natural killer cell-based (NK cell) therapeutics, today announced that members of its executive leadership team are scheduled to ...
Read More

-Proof-of-concept achieved for VY-UC to engineer donor cells without the complexities of gene-editing -Novel platform abrogates cellular immune response and obviates the need for immunosuppressive drugs TAMPA, FLORIDA & STOCKHOLM, SWEDEN – October 22, 2020 – Vycellix, Inc., an immuno-centric ...
Read More

VY-UC represents novel & simplified approach to design “off-the-shelf” therapies resolving the complexities & limitations of gene-editing to modulate self-recognition proteins  TAMPA, FLORIDA & STOCKHOLM, SWEDEN – August 10, 2020 – Vycellix, Inc., an immuno-centric discovery life science company with ...
Read More

TAMPA, FLORIDA & DUBLIN, IRELAND – March 25, 2020 – Vycellix™, Inc., an immuno-discovery cell & gene therapy company, and Avectas Limited, a cell engineering technology business, today jointly announced that the companies have entered into a collaboration agreement to ...
Read More

Vycellix Founders Awarded Innovation Grant by Sweden’s Vinnova to Establish New World-Class Research Environment on Development of Next-Generation Natural Killer Cell-based Cancer Immunotherapy Vycellix included as collaborative partner within the Center’s research constellation of prestigious academic & industry partners TAMPA, ...
Read More

SAB Comprised of Key Opinion Leaders Advancing Next-Generation Cell & Gene-based Immuno-Oncology Therapeutic Platforms TAMPA, FLORIDA & STOCKHOLM, SWEDEN – June 25, 2019 – Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned ...
Read More

TAMPA, FLORIDA & STOCKHOLM, SWEDEN – March 15, 2019 – Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned Karolinska Institutet, will present at the Innate Killer Summit 2019 to be held in ...
Read More

Vycellix is advancing pipeline of modulators and next-generation T cell & NK cell therapies for treatment of cancers Company to present on Cell Therapy Manufacturing Panel at Moffitt’s Business of Biotech Conference on Feb 22 TAMPA, FLORIDA & STOCKHOLM, SWEDEN ...
Read More